- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL); small lymphocytic lymphoma (SLL); mantle cell lymphoma
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 912KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 66KB)
Ibrutinib – November 2020
Ibrutinib: Tablet 140 mg, Tablet 280 mg, Tablet 420 mg, Tablet 560 mg; Imbruvica®
Last updated
5 March 2021